Tobira Is Focused On Developing And Commercializing Innovative Therapeutics To Treat Liver Diseasehuman Immunodeficiency Virusor Hiv 1Fibrosis And Inflammationits Lead Product Candidatecenicrivirocor Cvcis A Proprietary Immunomodulator That May Be Used To Treat A Number Of Diseasesincluding Nashkidney Fibrosishiv 1 And Otherstobira S Management Team Has Extensive Experience In Developing And Commercializing Therapeutics For Liver Disease And Hiv 1 The Lead Indication For Cvc Isnon Alcoholic Steatohepatitisor Nashfor Which Tobira Plans To Begin A Phase 2 Clinical Trial In The Second Half Of 2014The Company Believes There Are No Other Product Candidates In Development For Nash That Target The Immuno Inflammatory Pathways Responsible For Fibrosis Cvc Also Is Phase 3 Ready In Hiv 1 Infection With Potential As The Backbone In Afixed Dose Combination Therapycvc Is A Once Daily Pill With A Safety And Tolerability Profile That Has Been Established To Date In 550 Subjects Dosed In Completed Phase 1 And Phase 2 Trialsincluding 115 Hiv 1 Infected Subjects On Treatment For Up To 48 Weeks
No conferences found for this company.
| Company Name | Tobira Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
